Ticker LaunchReverse merger · Pending · SNTS
Santersus AG
Reverse merger with Xenetic Biosciences, Inc. (XBIO)
Santersus AG agreed to merge into Xenetic Biosciences, Inc. (XBIO), a Nasdaq biopharma advancing DNase technology, after strategic review, in a reverse merger that takes the private company public. The deal was announced on Sep 16, 2026. The combined company is expected to trade as Santersus Bio, Inc. (SNTS) on Nasdaq.
Santersus Bio, Inc. would combine Santersus's NucleoCapture selective blood purification technology, which has FDA Breakthrough Device Designation for sepsis and lupus programs, with Xenetic's DNase technology, both targeting neutrophil extracellular traps.
- Status
- Pending
- Private company
- Santersus AG
- Public company
- Xenetic Biosciences, Inc. (XBIO)
- Public company business before
- Nasdaq biopharma advancing DNase technology, after strategic review
- Announced
- Sep 16, 2026
- Combined company
- Santersus Bio, Inc. (SNTS)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Announcement 8-K Sep 16, 2026
- Announcement press release Sep 16, 2026
- All filings on EDGAR CIK 1534525
Other pending reverse mergers
- North Immunology, Inc.into Aethlon Medical, Inc. · Sep 17, 2026
- Ambros Therapeutics, Inc.into Werewolf Therapeutics, Inc. · Aug 21, 2026
- Slate Medicines, Inc.into Fulcrum Therapeutics, Inc. · Aug 17, 2026
- Redx Pharma Limitedinto Skye Bioscience, Inc. · Aug 14, 2026
- Caldera Therapeutics, Inc.into Synlogic, Inc. · Jul 29, 2026
- GH Power Inc.into Matinas BioPharma Holdings, Inc. · Jul 13, 2026